Drug Tariff Pro Ltd 15673972 false 2024-04-23 2025-04-30 2025-04-30 The principal activity of the company is business and domestic software development Digita Accounts Production Advanced 6.30.9574.0 true 15673972 2024-04-23 2025-04-30 15673972 2025-04-30 15673972 core:RetainedEarningsAccumulatedLosses 2025-04-30 15673972 core:ShareCapital 2025-04-30 15673972 core:CurrentFinancialInstruments 2025-04-30 15673972 core:CurrentFinancialInstruments core:WithinOneYear 2025-04-30 15673972 core:OfficeEquipment 2025-04-30 15673972 bus:SmallEntities 2024-04-23 2025-04-30 15673972 bus:AuditExemptWithAccountantsReport 2024-04-23 2025-04-30 15673972 bus:FilletedAccounts 2024-04-23 2025-04-30 15673972 bus:SmallCompaniesRegimeForAccounts 2024-04-23 2025-04-30 15673972 bus:Director1 2024-04-23 2025-04-30 15673972 bus:PrivateLimitedCompanyLtd 2024-04-23 2025-04-30 15673972 core:OfficeEquipment 2024-04-23 2025-04-30 15673972 countries:AllCountries 2024-04-23 2025-04-30 iso4217:GBP xbrli:pure

FINANCIAL PERIOD DATA REFRESH REQUIRED
Select the Refresh button on the Summary or Disclosure tab

Registration number: 15673972

Drug Tariff Pro Ltd
Unaudited Financial Statements
for the Period from 23 April 2024 to 30 April 2025

Drug Tariff Pro Ltd

(Registration number: 15673972)
Balance Sheet as at 30 April 2025

| Note | 2025 £
Fixed assets |  |
Tangible assets | 3 | 477
Current assets |  |
Debtors | 4 | 1,230
Cash at bank and in hand |  | 6,810
|  | 8,040
Creditors: Amounts falling due within one year | 5 | (8,248)
Net current liabilities |  | (208)
Net assets |  | 269
Capital and reserves |  |
Called up share capital |  | 100
Retained earnings |  | 169
Shareholders' funds |  | 269

For the financial period ending 30 April 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:

• | The members have not required the company to obtain an audit of its accounts for the period in question in accordance with section 476; and
• | The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime and the option not to file the Director's Report and the Profit and Loss Account has been taken.

These financial statements, which have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006 and in accordance with the provisions of FRS 102 Section 1A Small Entities, were approved and authorised for issue by the director on 18 September 2025

.........................................

C J Armstrong

Director

Drug Tariff Pro Ltd

Notes to the Unaudited Financial Statements for the Period from 23 April 2024 to 30 April 2025

1 | Accounting policies

Statutory information

Drug Tariff Pro Ltd is a private company, limited by shares, domiciled in England and Wales, company number 15673972. The registered office is at Farrier's Barn, 5 Castle Farm, Ladyfield Road, Thorpe Salvin, S80 3JN.

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A - 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006.

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value. The presentation currency is United Kingdom pounds sterling, which is the functional currency of the company. The financial statements are those of an individual entity.

Turnover

Turnover comprises the fair value of the consideration received for the provision of services in the ordinary course of the company's activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts. Turnover is recognised in line with service periods and subscriptions.

Tax

The tax expense for the period comprises current tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.
The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in countries where the company operates and generates taxable income.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

Tangible assets

Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.
The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Drug Tariff Pro Ltd

Notes to the Unaudited Financial Statements for the Period from 23 April 2024 to 30 April 2025 (continued)

1 | Accounting policies (continued)

Depreciation

Depreciation is charged so as to write off the cost of assets over their estimated useful lives, as follows:

Asset class | Depreciation method and rate
Office equipment | 25% straight line per annum

2 | Staff numbers

The average number of persons employed by the company (including the director) during the period, was 0.

3 | Tangible assets

| Office equipment £
Cost
Additions | 565
At 30 April 2025 | 565
Depreciation
Charge for the period | 88
At 30 April 2025 | 88
Carrying amount
At 30 April 2025 | 477

4 | Debtors

| 2025 £
Prepayments | 230
Other debtors | 1,000
| 1,230

Drug Tariff Pro Ltd

Notes to the Unaudited Financial Statements for the Period from 23 April 2024 to 30 April 2025 (continued)

5 | Creditors

| 2025 £
Due within one year |
Taxation and social security | 6,748
Accruals and deferred income | 1,500
| 8,248

6 | Related party transactions

During the year the director had an interest free loan with the company. At the balance sheet date the amount due to the company was £1,000.